- 1 Immunogenicity and safety of a monovalent Omicron XBB.1.5 SARS-CoV-2 recombinant spike protein
- 2 vaccine in previously unvaccinated, SARS-CoV-2 seropositive participants: primary day-28 analysis of a
- 3 phase 2/3 open-label study
- 4 **Authors:** Katia Alves, MD¹; Alex Kouassi, PhD¹; Joyce S. Plested, PhD¹; Raj Kalkeri, PhD¹; Katherine Smith,
- 5 MD¹; Muneer Kaba, MD¹; Joy Nelson, BS¹; Mingzhu Zhu, PhD¹; Shane Cloney-Clark, BS¹; Zhaohui Cai,
- PhD¹; Raburn M. Mallory, MD¹; and Fernando Noriega, MD¹ on behalf of the 2019nCoV-313 Study
 Investigators
- 8
- 9 **Affiliations**: ¹Novavax Inc., Gaithersburg, MD.
- 10
- ¹Novavax, Inc., 700 Quince Orchard Road, Gaithersburg, MD 20878, USA
- 12
- 13
- 14 Article Type: Article (original research; not randomized)
- 15
- 16 **Summary**: 292/300
- 17 Word Count: 3637/5000
- 18 Figures/Tables (10 limit): 4/3
- 19 **References:** 28/50 (total of 29 once 313 part 1 reference is formatted)
- 20
- 21 Corresponding Author:
- 22 Fernando Noriega
- 23 Novavax, Inc.
- 24 700 Quince Orchard Rd.
- 25 Gaithersburg, MD 20878, USA
- 26 fnoriega@Novavax.com
- 27

28 Abbreviations

- AESI, adverse event of special interest; ELISA, enzyme-linked immunosorbent assay; GMEU, geometric
- 30 mean ELISA unit; GMEUR, geometric mean ELISA unit ratio; GMT, geometric mean titer; GMTR,
- 31 geometric mean titer ratio; IQR, interquartile ratio; LB, lower bound; MAAE, medically attended adverse
- 32 event; N, nucleocapsid; nAb, neutralizing antibody; SAE, serious adverse event; SRR, seroresponse rate;
- 33 TEAE, treatment-emergent adverse event.
- 34

35 Summary (292/300)

36 Background

- 37 Most of the population has been infected with SARS-CoV-2 and, thus, is primed by natural exposure. As
- 38 such, it was assessed whether a single dose of the monovalent XBB.1.5 vaccine, NVX-CoV2601, elicited a
- 39 comparable immune response to XBB.1.5 in seropositive unvaccinated participants to that in previously
- 40 vaccinated participants, thereby allowing the former to forego a two-dose primary series.

41 Methods

- 42 In this phase 2/3, open-label, single-arm study (2019nCoV-313/NCT05975060 [part 2]), vaccine-naive
- 43 participants ≥18 years with previous SARS-CoV-2 infection received one dose of NVX-CoV2601. This
- analysis compared the 28-day immunogenicity and safety of NVX-CoV2601 in vaccine-naive and
- previously vaccinated (\geq 3 prior mRNA-based vaccines, from 2019nCoV-313 part 1) participants.
- 46 Noninferiority of neutralizing antibody (nAb) response in vaccine-naive versus vaccinated participants
- 47 was the primary objective. The day-28 geometric mean titer (GMT) ratio (GMTR) and seroresponse rate
- 48 (SRR; percentage of participants with a \geq 4-fold rise in antibody response from baseline) were measured,
- 49 and safety was assessed.

50 Results

- 51 Of the participants enrolled from September 11–November 15, 2023, per-protocol sets included
- 52 306/338 (90.5%) vaccine-naive and 309/332 (93.1%) vaccinated participants. At day 28, adjusted GMTs
- 53 (95% CI) against XBB.1.5 in the vaccine-naive and vaccinated groups were 1491.5 (1277.5–1741.4) and
- 54 841.4 (723.9–978.0), respectively. The vaccine-naïve—vaccinated nAb GMTR was 1.8 (95% Cl 1.43–2.20)
- and SRRs were 74.3% and 64.3% for vaccine-naive and vaccinated participants, respectively (SRR
- 56 difference: 10.0 [95% Cl 2.6–17.4]). No new safety signals or events of special interest were reported.

57 Conclusions

- 58 A single dose of NVX-CoV2601 in vaccine-naive participants with a history of SARS-CoV-2 infection
- elicited a robust neutralizing antibody response that was noninferior to that observed in vaccinated
- 60 participants. The vaccine was well-tolerated. These data support the use of NVX-CoV2601 as a single
- 61 dose, regardless of prior vaccination history.

62 Trial registration: NCT05975060

- 63
- 64
- 65
- 66 **Keywords (up to 6):** COVID-19, variant, vaccination, single-dose

67 **1. Introduction**

Variants of severe acute respiratory syndrome coronavirus (SARS-CoV-2) have evolved rapidly.^{1,2} 68 69 The high protective efficacy (\geq 90%) provided by prototype COVID-19 vaccines (BNT162b2 [Pfizer-BioNTech],³ mRNA-1273 [Moderna],⁴ and Matrix-M[™]–adjuvanted, recombinant spike (rS) protein 70 vaccine NVX-CoV2373 [Nuvaxovid[™]; Novavax, Inc.]^{5,6}) was demonstrated against ancestral SARS-CoV-2 or 71 72 early variants. Notably, immunity elicited by vaccination or natural infection wanes, and the emergence of immune-evasive variants⁷ suggests the need for updates to vaccine strain composition. The World 73 74 Health Organization (WHO), European Medicines Agency, and United States Food and Drug 75 Administration (US FDA) recommended updating COVID-19 vaccines to have a monovalent XBB.1.5 composition for the 2023–2024 season.⁸⁻¹⁰ In consideration of this guidance, a monovalent XBB.1.5 76 77 subvariant-specific vaccine (NVX-CoV2601) was produced based on the same rS protein technology used 78 for the authorised prototype, NVX-CoV2373. NVX-CoV2601 received authorisation for use in Canada, the European Union (EU), the US, and by the WHO in 2023.¹¹⁻¹⁴ 79 80 Immunogenicity and safety of NVX-CoV2601 are being evaluated in the phase 2/3, open-label 81 2019nCoV-313 study (NCT05975060) in two populations representative of the US population vaccination 82 status (part 1: previously vaccinated adults who received \geq 3 doses of an mRNA vaccine; part 2: vaccine-83 naive adults who previously had a SARS-CoV-2 infection, as determined by the presence of antinucleocapsid [anti-N] antibodies). Results from part 1 showed that in previously vaccinated participants, 84 85 NVX-CoV2601 induced superior antibody responses to XBB.1.5 compared with those observed in a historical control group of participants who received the prototype vaccine, NVX-CoV2373.¹⁵ 86 87 While an estimated 70% of the US population has completed a primary COVID-19 vaccination 88 series as of December 31, 2023, approximately 20% had not received any COVID-19 vaccine doses.¹⁶ 89 Considering this population, part 2 of the 2019nCoV-313 study aimed to evaluate safety and 90 immunogenicity of a single dose of NVX-CoV2601 administered to unvaccinated participants with a prior SARS-CoV-2 infection. In this case, the unvaccinated population should have some baseline immunity 91 from previous infection, as infection-induced seroprevalence is widespread.^{17,18} A nationwide survey 92 93 conducted from October–December 2023 showed that ~87% of the US population (age ≥16 years) had infection-induced seroprevalence (i.e., anti-SARS-CoV-2 spike or nucleocapsid antibodies).¹⁷ In this 94 setting, it is possible that a single dose of the updated Matrix-M[™]-adjuvanted, rS protein vaccine would 95 96 result in adequate and robust immunogenicity in a population whose immune system was not primed by prior COVID-19 vaccination.^{18,19} 97

Here, we report results from the primary day-28 analysis from part 2 of the 2019nCoV-313 study.
In this analysis, neutralizing antibody (nAb) responses elicited by a single dose of NVX-CoV2601,
administered to unvaccinated participants with evidence of prior SARS-CoV-2 infection, were evaluated
for noninferiority to observed responses to a single dose of NVX-CoV2601 in vaccinated participants who

- 102 had previously received \geq 3 doses of a COVID-19 mRNA vaccine.
- 103

104 2. Methods

105 *2.1 Study design and participants*

Part 2 of the phase 2/3, open-label, single-arm 2019nCoV-313 study (NCT05975060) is being 106 107 conducted across 30 US sites and has enrolled medically stable males and non-pregnant females aged 108 ≥18 years who were COVID-19 vaccine–naive and had a clinical history of COVID-19–like disease in the 109 previous year. Prior COVID-19-like disease occurrence was collected per participant disclosure at 110 enrollment; time since illness details were not provided. Participants with baseline SARS-CoV-2 111 seropositivity (anti-N serum lgG) were assessed for the primary immunogenicity endpoint (Figure S1). 112 Exclusion criteria included receipt of any investigational vaccine within 90 days before study vaccination 113 and/or receipt of influenza vaccination ≤ 14 days or of any other approved vaccination ≤ 30 days before 114 the study vaccination; history of myocarditis/pericarditis; anaphylaxis to any vaccine or allergy to vaccine 115 components; alcohol abuse within 2 years of study vaccination; autoimmune or immunodeficiency 116 disease/condition requiring ongoing therapy; or active cancer treated within 3 years of the first study 117 vaccination. This planned primary analysis includes data through day 28. Additional study details can be 118 found in the study protocol in Appendix B.

The comparator group came from part 1 of the 2019nCoV-313 study, conducted separately, and consisted of participants who had previously received ≥3 doses of mRNA-1273 or BNT162b2 monovalent or bivalent vaccines, with the last dose administered ≥90 days before study vaccination¹⁵, hereafter referred to as the vaccinated group. Aside from criteria related to previous COVID-19 vaccination and SARS-CoV-2 seropositive status, parts 1 and 2 of the study had the same eligibility criteria.

The study protocol was approved by Advarra, Inc. (Columbia, MD, USA), and the study was conducted according to the principles of the International Conference on Harmonization Good Clinical Practice Guideline, adopting the principles of the Declaration of Helsinki, as well as all applicable national, state, and local laws and regulations. All participants provided written informed consent.

128 2.2 Procedures

129Participants in both groups received a single dose of NVX-CoV2601 on day 0 (Figure S1) and130remained on study for data collection, with scheduled visits at days 28, 90 (phone visit), and 180.131NVX-CoV2601 (5 µg SARS-CoV-2 rS protein from XBB.1.5 and 50 µg Matrix-M[™] adjuvant) was132administered via a 0.5-mL intramuscular injection. Study vaccine was manufactured by the Serum133Institute of India, Pvt., Ltd. (Pune, India) in collaboration with Novavax, Inc. Participants in parts 1 and 2134received doses of NVX-CoV2601 from the same vaccine lot and remained in the clinic or under135observation for ≥15 min post vaccination for monitoring.

Safety was evaluated throughout the study. Participants completed an eDiary to record solicited
reactogenicity for 7 days post vaccination. Reports of unsolicited treatment-emergent adverse events
(TEAEs) were collected for 28 days following vaccination. Serious TEAEs (SAEs), treatment-related
medically attended adverse events (MAAEs), and adverse events of special interest (AESIs) were
collected through day 180 (end of study).

141 SARS-CoV-2 polymerase chain reaction (PCR) swab testing was performed on day 0. Baseline 142 serostatus was determined through qualitative detection of SARS-CoV-2 anti-N antibodies identified in 143 blood samples collected on day 0; an additional sample was collected on day 28. Blood samples for central evaluation of immunogenicity (Novavax Clinical Immunology, Gaithersburg, MD, USA) were 144 145 collected on days 0 and 28, with additional samples to be collected on day 180. Serum was analyzed using a validated pseudovirus neutralization assay with an inhibitory dilution of 50% (ID_{50}),²⁰ anti-rS 146 immunoglobulin G (IgG) enzyme-linked immunosorbent assay (ELISA).²¹ and anti-N serology.²² nAb 147 148 responses to emerging SARS-CoV-2 strains were assessed with fit-for-purpose pseudovirus neutralization 149 assays in a subset of participant samples that had sufficient serum remaining for testing, and were 150 selected through a random number generator.

151 *2.3 Outcomes*

152 The primary objective was to determine whether NVX-CoV2601 elicited a noninferior nAb 153 response in SARS-CoV-2-seropositive vaccine-naive participants compared with vaccinated participants. 154 Co-primary endpoints were day-28 nAb geometric mean titers (GMTs) and the proportion of participants 155 who seroconverted (seroresponse rate [SRR]) based on ID₅₀ titers to Omicron XBB.1.5). SRR was defined 156 as the percentage of participants with a \geq 4-fold rise in antibody response from baseline. IgG antibody 157 responses to XBB.1.5 were evaluated as a secondary endpoint. Post-hoc analyses included nAb 158 responses by age group and responses to emerging SARS-CoV-2 variants, evaluated in a subset of the 159 per-protocol analysis set.

160 The secondary objective to evaluate the safety of NVX-CoV2601 used the following endpoints: 161 solicited reactogenicity through 7 days post vaccination; unsolicited TEAEs through day 28; and related 162 MAAEs, AESIs and SAEs through day 180. TEAEs were coded (Medical Dictionary for Regulatory Activities, 163 version 26.0) and graded (FDA toxicity grading scale). Solicited reactogenicity events included local (pain, 164 tenderness, redness, and swelling) and systemic (fever, nausea/vomiting, headache, fatigue/malaise, 165 myalgia, and joint pain) reactions. MAAEs were any TEAE leading to an unscheduled healthcare 166 practitioner visit. AESIs included potential immune-medicated medical conditions, myocarditis, 167 pericarditis, and/or COVID-19-specific complications. SAEs were TEAEs associated with death; 168 hospitalization; persistent or significant incapacity or substantial disruption to normal life; congenital 169 anomaly; or other serious, important medical events.

170 2.4 Statistical analysis

171 Noninferiority of NVX-CoV2601 in vaccine-naive versus vaccinated participants was based on FDA industry guidance²³ and required meeting two hypotheses: (1) noninferiority based on a GMT ratio 172 173 (GMTR) with a lower bound of the two-sided 95% confidence interval (CI) exceeding 0.67, and (2) 174 noninferiority based on an SRR difference with the lower bound of the two-sided 95% Cl greater than – 175 10%. The 28-day immunogenicity assessments were completed in the per-protocol analysis set, which 176 included all participants who received the study vaccine and had no major protocol violations or events 177 considered clinically relevant to the immune response (e.g., PCR-positive on day 0) before the data-178 extraction date and who had days 0 and 28 serology. Participants in the vaccine-naive group were 179 excluded from the per-protocol analysis set if their baseline anti-N result was negative or missing.

180 A sample size of 330 participants was determined based on the co-primary endpoints. 181 Assumptions to achieve at least 95% power for GMTR noninferiority were: a standard deviation of 0.6 for log-transformed neutralization titers, a 25% attrition rate, and an overall one-sided Type I error rate of 182 183 2.5%. The sample size of 330 participants provided a likelihood of detecting rare TEAEs, with probability-184 risk combinations determined from the actual sample size (not the sample size adjusted for the attrition 185 rate). Specifically, there was a probability of detecting at least one TEAE of 91.89% if the true incidence 186 was 0.010; probabilities were 89.57%, 86.57%, 82.73%, 77.79%, and 71.44% if the true incidences were 187 0.009, 0.008, 0.007, 0.006, and 0.005, respectively. Secondary immunogenicity endpoints were 188 descriptively summarised.

189 GMTs and geometric mean ELISA units (GMEUs) were calculated as the antilog of the mean of
 190 the log-transformed titers at day 28 to generate a normal distribution. An analysis of covariance with
 191 vaccine group (vaccine-naive versus vaccinated) as a fixed effect and baseline value (day 0) as covariate

192 was performed to estimate the adjusted GMT and GMTR, and account for baseline differences among 193 the groups. The same methodology was used to estimate adjusted GMEUs and GMEU ratios (GMEURs). 194 The mean difference and corresponding CI limits between vaccine groups were exponentiated to GMTRs 195 and GMEURs and corresponding 95% CIs. The 95% CIs for adjusted GMTs and GMTRs were calculated 196 based on the *t*-distribution of the log-transformed values, then back transformed to the original scale. 197 SRR two-sided exact binomial 95% CIs were calculated using the Clopper-Pearson method; SRR 198 differences (vaccine-naive-vaccinated) were computed along with their corresponding two-sided 95% 199 Cls, based on the method of Miettinen and Nurminen.

The safety analysis set included all participants who provided consent and received study vaccine; the safety set was analysed as actually treated. The descriptive safety analysis included summaries of the number and percentage of participants with solicited (local and systemic) TEAEs through 7 days and unsolicited AEs through 28 days after the study vaccination. Two-sided exact 95% Cls using the Clopper–Pearson method were included. The interim analysis included a descriptive summary of all MAAEs, AESIs, and SAEs through 28 days post study vaccination. SAS® software (version 9.4; SAS Institute Inc., Cary, NC, USA) was used for all statistical analyses.

207

208 **3. Results**

209 3.1 Participants

210 Between September 11, 2023 and November 15, 2023, 338/419 (80.7%) participants were 211 enrolled in part 2 of the study, after eligibility screening; there were 81 screen failures (Figure 1). At the 212 data extraction date (February 21, 2024), 322/338 (95.3%) participants were in follow-up and 16/338 213 (4.7%) discontinued (reasons: 4 [1.2%] participant withdrawal; 10 [3.0%] lost to follow-up; 1 [0.3%] 214 investigator decision [0.3%]; 1 [0.3%] other). No participant discontinued the study because of a TEAE. 215 All 338 participants were included in the safety analysis set. The per-protocol analysis set included 216 306/338 (90.5%) participants; reasons for exclusion were negative baseline anti-N (23/338; 6.8%), 217 positive baseline PCR (5/338; 1.5%), and protocol violation (5/338; 1.5%; one patient had a protocol 218 violation and positive PCR result). For the vaccinated group, 329/332 (99.1%) participants were in follow-219 up at the data extraction date. All 332 participants were included in the safety analysis set, and the perprotocol analysis set included 309/332 (93.1%) participants. The vaccinated group (from part 1 of the 220 study) was enrolled from September 7–8, 2023¹⁵ and included 332 and 309 participants in the safety and 221 222 per-protocol analysis sets, respectively.

223 Some differences were observed in participant demographics for the vaccine-naive and 224 vaccinated groups (Table 1). In the per-protocol analysis set, median age (IQR) was 38 years (31-49) in 225 the vaccine-naive group and 53 years (40–65) in the vaccinated group. Most participants in the vaccine-226 naive group identified as either White (152/306 [49.7%]) or Black/African American (132/306 [43.1%]). 227 In the vaccinated group, most participants identified as White (231/309 [74.8%]), and a smaller 228 proportion identified as Black/African American (47/309 [15.2%]). Most participants in the vaccinated 229 group had previously received three (129/309 [41.7%]) or four (109/309 [35.3%]) doses of an mRNA-230 based COVID-19 vaccine. Baseline demographics and participant characteristics were similar between 231 the per-protocol and safety analysis sets (Table S1).

232 *3.2 Immunogenicity*

233 The study met the two co-primary objectives; NVX-CoV2601 elicited a noninferior nAb response 234 in vaccine-naive participants compared with vaccinated participants (Table 2). At day 0, nAb GMTs 235 against XBB.1.5 were lower in the vaccine-naive group (67.6 [95% Cl 56.8-80.4]) compared with the 236 vaccinated group (120.8 [101.5–143.8]) (Figure 2A). At day 28, the increase in nAb GMTs from day 0 was 237 19.3-fold in the vaccine-naive group (GMT: 1303.7 [1087.4–1563.0]; adjusted GMT: 1491.5 [1277.5– 238 1741.4]) and 7.9-fold in the vaccinated group (GMT: 955.5 [95% Cl 814.0–1121.4]; adjusted GMT: 841.4 239 [723.9–978.0]). The nAb response was similar between groups (Figure 2B). The GMTR between the 240 groups at day 28 was 1.8 (95% Cl 1.43–2.20) (Figure 2C). From day 0 to 28, SRRs were 74.3% and 64.3% 241 for the vaccine-naive and vaccinated groups, respectively, with an SRR difference of 10.0 (95% Cl 2.6– 242 17.4). When assessed by age group, nAb GMTs (95% CI) in participants aged 18–54 years increased from day 0 to 28 by 18.4-fold in the vaccine-naive group (GMT: 1208.3 [993.1–1470.2]; adjusted GMT: 1337.6 243 244 [1125.3–1589.9]) and 8.4-fold in the vaccinated group (GMT: 1027.9 [829.5–1090.9]; adjusted GMT: 245 880.6 [710.9–1090.9]) (Figure S2). Increases in nAb GMTs were also observed in participants aged ≥55 246 years: 25.6-fold in the vaccine-naive group (GMT: 2009.9 [1250.4–3231.0]; adjusted GMT: 2364.3 247 [1633.0–3423.1]) and 7.4-fold in the vaccinated group (GMT: 880.5 [95% Cl 691.2–1121.5]; adjusted 248 GMT: 838.8 [685.6–1026.1]). The anti-rS IgG GMEU on day 0 in the vaccine-naive group was 5218.1 (95% 249 Cl 4339.6–6274.5), whereas it was 23701.1 (21042.3–26695.8) in the vaccinated group, a median of ~12 250 months after their most recent COVID-19 vaccination (Table S2). On day 28, GMEU levels increased in 251 both groups (adjusted GMEUs: 60691.2 [54585.2–67480.3] and 79761.5 [73603.5–86434.7], 252 respectively). Descriptive results of the anti-rS IgG analyses were consistent with the nAb analyses, with 253 similar anti-rS lgG titers and SRRs between groups.

Based on a subset of samples from the vaccine-naive group (n=42), GMTs against additional SARS-CoV-2 variants increased from day 0 to 28 (**Figure 3**). At day 0, the GMT (95% CI) against JN.1 was 51.2 (33.5–78.3), which increased to 486.4 (310.0–763.2) at day 28 (GMFR: 9.5). Day 0 and day 28 GMTs (95% CI), respectively, against KP.2 were 44.2 (28.5–68.6) and 360.4 (232.7–558.2), with a GMFR of 9.1. Among the variants analyzed in this subset, the highest baseline and day 28 titers (and GMFR) were observed against XBB.1.5.

260 *3.3 Safety*

Within 7 days of study vaccine administration, 140/338 (41.4%) vaccine-naive participants and 189/332 (56.9%) vaccinated participants reported a local solicited TEAE (Figure 4; Table 3). The most common (occurring in >20% of participants) solicited local event was pain/tenderness (combined proportion), reported in 140/338 (41.4%) and 186/332 (56.0%) of the vaccine-naive and vaccinated groups, respectively (median duration: 2 days in both groups). Three (0.9%) participants in the vaccinenaive group (grade 3 pain/tenderness) and one (0.3%) in the vaccinated group (grade 3 pain/tenderness) had solicited local TEAEs of grade ≥3.

268 Solicited systemic TEAEs within 7 days of study vaccine were reported in 164/338 (48.5%) 269 vaccine-naive and 158/332 (47.6%) vaccinated participants. The most common solicited systemic events 270 were fatigue/malaise (vaccine-naive: 98/338 [29.0%]; vaccinated: 109/332 [32.8%]), muscle pain 271 (106/338 [31.4%]; 97/332 [29.3%]), and headache (92/338 [27.2]; 74/332 [22.3%]). Median durations of 272 fatigue/malaise were 2 days in both groups; muscle pain and headache both had median durations of 2 273 days in the vaccine-naive group and 1 day in the vaccinated group. Few participants reported a solicited 274 event of fever (vaccine-naive: 3/338 [0.9%]; vaccinated: 2/332 [0.6%]). Grade ≥3 solicited systemic TEAEs 275 were reported in 7/338 (2.1%) and 4/332 (1.2%) participants in the vaccine-naive and vaccinated groups, 276 respectively, none of which were grade 4.

277 Through 28 days post-vaccination, unsolicited TEAEs were reported in 18/338 (5.3%) and 29/332 278 (8.7%) participants in the vaccine-naive and vaccinated groups, respectively (Table 3; Table S3). Few 279 participants reported treatment-related unsolicited TEAEs. Among 8/338 (2.4%) and 14/332 (4.2%) 280 participants with an MAAE in the vaccine-naive and vaccinated groups, respectively, one MAAE of grade 281 2 hypertension in a participant from the vaccinated group was considered treatment-related. SAEs and 282 severe TEAEs were reported in <1% of participants in either group; none were considered treatment-283 related. There were no reported events of myocarditis, pericarditis, or any other AESI. No participant 284 discontinued the study because of a TEAE, and no deaths were reported.

285

286 4. Discussion

In this primary day-28 analysis of part 2 of the 2019nCoV-313 study, immunogenicity of a single
dose of the monovalent XBB.1.5 vaccine (NVX-CoV2601), resulted in robust immunogenicity in vaccinenaive participants seropositive for SARS-CoV-2 N-protein, and no new safety signals were identified. The
co-primary endpoints of noninferiority of the GMTR and SRR difference between vaccine-naive and
vaccinated participants, who both received single study doses of NVX-CoV2601, were met.

292 Robust increases in nAbs were observed for both study groups after receipt of NVX-CoV2601. 293 Notably, a greater increase in titer was observed from day 0 to 28 in the vaccine-naive group (19.3-fold 294 increase in GMT) compared with the vaccinated group (7.9-fold increase). This observation may be 295 related to lower baseline titers and lower median age in the vaccine-naive group, as increasing age has been associated with immunosenescence and decreased vaccine-related immunity.²⁴ However, a post-296 297 hoc analysis evaluating nAb response by age found that 28-day nAb titers were higher in vaccine-naive 298 compared with previously vaccinated participants in both age groups (18–54 and \geq 55 years). To help 299 address reduction in immune titers over time in older adults, an additional dose of the monovalent 300 XBB.1.5 vaccine was recommended by regulatory authorities for the spring of 2024 for older adults and those who are immunocompromised.²⁵ 301

302 The overwhelming majority of the US population has been infected with SARS-CoV-2, received a COVID-19 vaccination, or both.^{17,26} In a nationwide study of US blood donors, 87% had anti-N antibodies 303 304 indicating a past infection, and combined seroprevalence from infection or vaccination reached 98% by the end of 2023.¹⁷ In this epidemiologic environment, a single dose of NVX-CoV2601 led to a similar nAb 305 306 response between vaccine-naive and previously vaccinated participants, suggesting that a single dose 307 was sufficient to augment immunogenicity derived from natural infection. Other studies have shown 308 that one vaccine dose in unvaccinated people post SARS-CoV-2 infection can induce a substantial immune response that is comparable to, if not greater than, that observed in those who have received 309 two vaccine doses.^{18,19} Overall, amidst high population-wide seroprevalence, priming via vaccination 310 (e.g., two doses administered 21 days apart) no longer seems necessary for adequate immunogenicity, 311 312 and these data from the 2019nCov-313 study support the use of NVX-CoV2601 as a single dose in 313 unvaccinated individuals.

The rapid evolution of SARS-CoV-2 variants led to an updated monovalent XBB.1.5 vaccine composition for 2023–2024⁸⁻¹⁵ and recent authorization of another updated vaccine targeting the JN.1 lineage for 2024–2025^{8,27}. Vaccination with a single dose of NVX-CoV2601 elicited robust immunogenicity against XBB.1.5 in vaccine-naive and vaccinated individuals, as well as cross-reactivity

with variants that have emerged since XBB.1.5 in the vaccine-naive group (i.e., approximately 10-fold
increases in nAb GMTs against JN.1 and lineage subvariants, including KP.2). Cross-reactivity has also
been reported separately in the vaccinated group.¹⁵ These findings supported recommendations for the
spring 2024 vaccination campaign in vulnerable individuals such as older adults and those with
weakened immune systems.²⁵ However, titers against these variants were approximately 50–75% lower
compared with the titers against XBB.1.5, suggesting a benefit to periodic COVID-19 vaccine updates to
align with predominantly circulating strains, such as that seen for 2024–2025.²⁷

325 This study is an open-label study without randomization. Participants were sequentially enrolled 326 in study groups in two separate parts, which allowed for an earlier evaluation of the safety and 327 immunogenicity of a single dose of NVX-CoV2601 in part 1 (\geq 3 mRNA previously vaccinated participants) 328 followed by enrollment of vaccine-naive participants with previous SARS-CoV-2 infection in part 2. 329 Participants were recruited from the same set of study sites and enrollment was sequential; therefore, both populations were exposed to similar SARS-CoV-2 strains circulating at this time (e.g., XBB-lineage 28), 330 331 and any differences among the groups likely reflect differences typically observed among COVID-19– 332 vaccinated and –unvaccinated individuals in the general US population. Notably, enrollment of participants who had remained unvaccinated for the 3 years since vaccines against SARS-CoV-2 first 333 334 became available, and would consent to study vaccination, was anticipated to be a challenge. As such, a 335 limitation of the study is some differences in participant demographics (e.g., age, race, and sex) and prior 336 COVID-19-like disease occurrence between the study groups. Specifically, the vaccine-naive group had 337 larger proportions of participants with demographics associated with vaccine hesitancy, such as younger age and Black/African American race.²⁹ 338

In summary, a single dose of NVX-CoV2601 elicited robust immunogenicity in vaccine-naive participants with prior SARS-CoV-2 infection. In this population, immunogenicity of NVX-CoV2601 was noninferior to that observed in participants who previously received ≥3 mRNA vaccinations. Additionally, the safety and reactogenicity profile of the updated vaccine targeting the XBB.1.5 strain, NVX-CoV2601, was consistent with that of the prototype vaccine, NVX-CoV2373⁵. Amidst high seroprevalence in the US, these data support the use of single doses of the Novavax vaccine to elicit immunity against SARS-CoV-2, regardless of prior vaccination history.

346

347 Acknowledgments

- 348 We thank all the study participants who volunteered for this study. We also thank Sharon Glass, MLIS, of
- 349 Novavax, Inc., for providing literature research support, and Gordon Chau, MS, of Novavax, Inc., for
- 350 statistical support. Medical writing, editing, and formatting support, under the direction of the authors,
- 351 was provided by Meredith Kalish, MD, CMPP and Ebenezer M. Awuah-Yeboah, BS, of Ashfield
- 352 MedComms (US), an Inizio company, and was funded by Novavax, Inc.
- 353 Appendix A. Supplementary data
- 354 Supplementary study details and results.
- 355
- 356 Appendix B. Study protocol
- 357 2019nCoV-313 study protocol.
- 358
- 359 Funding
- 360 Novavax, Inc. funded the 2019nCoV-313 study and provided the vaccine. Novavax, Inc.
- 361 collaborated with the investigators on the protocol, data analysis and interpretation, and preparation of
- 362 this paper.
- 363
- 364 **CRediT authorship contribution statement**
- 365 Katia Alves: Validation; Writing reviewing & editing
- 366 Alex Kouassi: Conceptualization; Formal analysis; Validation; Writing reviewing & editing
- 367 Joyce S. Plested: Formal analysis; Writing reviewing & editing
- 368 Raj Kalkeri: Methodology; Formal analysis; Writing reviewing & editing
- 369 **Katherine Smith**: Formal analysis; Writing reviewing & editing
- 370 Muneer Kaba: Formal analysis; Writing reviewing & editing
- 371 Joy Nelson: Project administration; Writing reviewing & editing
- 372 Mingzhu Zhu: Formal analysis; Writing reviewing & editing
- 373 Shane Cloney-Clark: Formal analysis; Writing reviewing & editing
- 374 Zhaohui Cai: Formal analysis; Writing reviewing & editing
- 375 **Raburn M. Mallory**: Conceptualization; Writing reviewing & editing
- 376 Fernando Noriega: Conceptualization; Validation; Writing reviewing & editing
- 377
- 378

379 Data Statement

380 Study information is available online at https://www.clinicaltrials.gov/study/NCT05975060. Requests

- submitted to the corresponding author will be considered upon publication of this article. The study
- 382 protocol is available in Appendix B.
- 383

384 **Declaration of Competing Interest**

Katia Alves reports a relationship with Novavax Inc that includes: employment and equity or stocks. Alex
Kouassi reports a relationship with Novavax Inc that includes: employment and equity or stocks. Joyce S.
Plested reports a relationship with Novavax Inc that includes: employment and equity or stocks. Raj
Kalkeri reports a relationship with Novavax Inc that includes: employment and equity or stocks.
Katherine Smith reports a relationship with Novavax Inc that includes: employment and equity or stocks.
Muneer Kaba reports a relationship with Novavax Inc that includes: employment and equity or stocks.
Joy Nelson reports a relationship with Novavax Inc that includes: employment and equity or stocks.

392 Mingzhu Zhu reports a relationship with Novavax Inc that includes: employment and equity or stocks.

393 Shane Cloney-Clark reports a relationship with Novavax Inc that includes: employment and equity or

394 stocks. Zhaohui Cai reports a relationship with Novavax Inc that includes: employment and equity or

395 stocks. Raburn M. Mallory reports a relationship with Novavax Inc that includes: employment and equity

396 or stocks. Fernando Noriega reports a relationship with Novavax Inc that includes: employment and

397 equity or stocks. This study was funded by Novavax, Inc. The authors received medical writing and

editorial support funded by the study sponsor. If there are other authors, they declare that they have no

known competing financial interests or personal relationships that could have appeared to influence thework reported in this paper.

- 401
- 402

403 References

404 Ao D, He X, Hong W, Wei X. The rapid rise of SARS-CoV-2 Omicron subvariants with immune 1. 405 evasion properties: XBB.1.5 and BQ.1.1 subvariants. MedComm (2020) 2023; 4(2): e239. 406 Nextstrain.org. Genomic epidemiology of SARS-CoV-2 with subsampling focused on North 2. 407 America since pandemic start. 29 April 2024. https://nextstrain.org/ncov/gisaid/north-america/all-408 time?dmin=2023-01-01&f region=North%20America. 409 Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 3. 410 vaccine. N Engl J Med 2020; 383(27): 2603-15. 411 4. Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. 412 N Engl J Med 2021; **384**(5): 403-16. 413 Dunkle LM, Kotloff KL, Gay CL, et al. Efficacy and safety of NVX-CoV2373 in adults in the United 5. 414 States and Mexico. N Engl J Med 2022; 386(6): 531-43. 415 Heath PT, Galiza EP, Baxter DN, et al. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. N 6. 416 Engl J Med 2021; 385(13): 1172-83. 417 Menegale F, Manica M, Zardini A, et al. Evaluation of Waning of SARS-CoV-2 Vaccine-Induced 7. 418 Immunity: A Systematic Review and Meta-analysis. JAMA Netw Open 2023; 6(5): e2310650. 419 8. World Health Organization. Statement on the antigen composition of COVID-19 vaccines. 18 May 420 2023. https://www.who.int/news/item/18-05-2023-statement-on-the-antigen-composition-of-covid-19-421 vaccines. 422 9. U.S. Food and Drug Administration. Recommendation for the 2023-2024 formula of COVID-19 423 vaccines in the U.S. <u>https://www.fda.gov/media/169591/download</u>. 424 European Medicines Agency. EMA and ECDC statement on updating COVID-19 vaccines to target 10. 425 new SARS-CoV-2 virus variants. https://extranet.who.int/pregual/vaccines/covid-19-vaccines-who-426 emergency-use-listing (accessed 27 March 2024. 427 World Health Organization. COVID-19 vaccines with WHO emergency use listing. 11. 428 https://extranet.who.int/prequal/vaccines/covid-19-vaccines-who-emergency-use-listing. 429 12. Novavax. Novavax's updated COVID-19 vaccine now authorized in Canada. 5 December 2023. 430 https://ir.novavax.com/press-releases/2023-12-05-Novavaxs-Updated-COVID-19-Vaccine-Now-431 Authorized-in-Canada. 432 13. European Medicines Agency. Nuvaxovid. 20 March 2024. 433 https://www.ema.europa.eu/en/documents/product-information/nuvaxovid-epar-product-434 information en.pdf. 435 U.S. Food and Drug Administration. FDA authorizes updated Novavax COVID-19 vaccine 14. 436 formulated to better protect against currently circulating variants. 3 October 2023. 437 https://www.fda.gov/news-events/press-announcements/fda-authorizes-updated-novavax-covid-19-438 vaccine-formulated-better-protect-against-currently. 439 Alves K, Kotloff K, McClelland RS, et al. Immunogenicity and safety of a monovalent Omicron 15. 440 XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis 441 of a phase 2/3 open-label study. Lancet Infect Dis 2024; Under review. 442 World Health Organization. COVID-19 vaccination, United States of America data. 2023. 16. 443 https://data.who.int/dashboards/covid19/vaccines?m49=840. 444 17. Centers for Disease Control and Prevention. 2022-2023 nationwide COVID-19 infection- and 445 vaccination-induced antibody seroprevalence (blood donations). 18 April 2024. 446 https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence-2022. 447 Krammer F, Srivastava K, Alshammary H, et al. Antibody responses in seropositive persons after a 18. 448 single dose of SARS-CoV-2 mRNA vaccine. N Engl J Med 2021; 384(14): 1372-4.

449 Zar HJ, MacGinty R, Workman L, et al. Natural and hybrid immunity following four COVID-19 19. 450 waves: A prospective cohort study of mothers in South Africa. EClinicalMedicine 2022; 53: 101655. 451 Cai Z, Kalkeri R, Zhu M, et al. A Pseudovirus-Based Neutralization Assay for SARS-CoV-2 Variants: 20. 452 A Rapid, Cost-Effective, BSL-2-Based High-Throughput Assay Useful for Vaccine Immunogenicity 453 Evaluation. Microorganisms 2024; 12(3). 454 Zhu M, Cloney-Clark S, Feng SL, et al. A Severe Acute Respiratory Syndrome Coronavirus 2 Anti-21. 455 Spike Immunoglobulin G Assay: A Robust Method for Evaluation of Vaccine Immunogenicity Using an 456 Established Correlate of Protection. *Microorganisms* 2023; **11**(7). 457 Madhi SA, Moodley D, Hanley S, et al. Immunogenicity and safety of a SARS-CoV-2 recombinant 22. 458 spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, 459 controlled, phase 2A/2B trial. Lancet HIV 2022; 9(5): e309-e22. 460 U.S. Food and Drug Administration. Guidance for Industry Clinical Data Needed to Support the 23. 461 Licensure of Seasonal Inactivated Influenza Vaccines. May 2007 2007. 462 https://www.fda.gov/media/73706/download (accessed September 4, 2024. 24. 463 Hou Y, Chen M, Bian Y, et al. Insights into vaccines for elderly individuals: from the impacts of 464 immunosenescence to delivery strategies. NPJ Vaccines 2024; 9(1): 77. 465 25. Centers for Disease Control and Prevention. Evidence to recommendations framework: 466 additional dose of 2023-2024 formula COVID-19 vaccine in older adults. 28 February 2024. 467 https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2024-02-28-29/06-COVID-Wallace-468 508.pdf. 469 26. Centers for Disease Control and Prevention. Adult coverage and intent. 2024. 470 https://www.cdc.gov/vaccines/imz-managers/coverage/covidvaxview/interactive/adult-coverage-471 vaccination.html. 472 U.S. Food and Drug Administration. Novavax COVID-19 Vaccine, Adjuvanted (2024-2025 27. 473 Formula) Authorized For Individuals 12 Years of Age and Older. September 3, 2024 2024. 474 https://www.fda.gov/vaccines-blood-biologics/coronavirus-covid-19-cber-regulated-biologics/novavax-475 covid-19-vaccine-adjuvanted (accessed September 4, 2024. 476 Nextstrain.org. Genomic epidemiology of SARS-CoV-2 with subsampling focused on North 28. 477 America since pandemic start [study period]. September 3, 2024 2024.

- 478 <u>https://nextstrain.org/ncov/gisaid/north-america/all-time?dmax=2023-12-01&dmin=2023-08-01</u>
- 479 (accessed September 3, 2024.
- 480 29. Pingali C, Meghani M, Razzaghi H, et al. COVID-19 Vaccination Coverage Among Insured Persons
- 481 Aged >/=16 Years, by Race/Ethnicity and Other Selected Characteristics Eight Integrated Health Care
- 482 Organizations, United States, December 14, 2020-May 15, 2021. MMWR Morb Mortal Wkly Rep 2021;
- 483 **70**(28): 985-90.
- 484
- 485

	Vaccine-naive (N=306)	Vaccinated (N=309)
Age, years		
Mean (SD)	40 (12.91)	52.1 (16.10)
Median (IQR)	38 (31–49)	53 (40–65)
Age, category, n (%)	<u>.</u>	
18 to 54 years	263 (85.9)	163 (52.8)
≥55 years	43 (14.1)	146 (47.2)
Sex, n (%)	· · · · ·	
Female	177 (57.8)	192 (62.1)
Male	129 (42.2)	117 (37.9)
Race, n (%)		
White	152 (49.7)	231 (74.8)
Black/African American	132 (43.1)	47 (15.2)
Native American/Alaska Native	6 (2.0)	6 (1.9)
Asian	2 (0.7)	12 (3.9)
Native Hawaiian/other Pacific Islander	1 (0.3)	2 (0.6)
Multiple	5 (1.6)	3 (1.0)
Other	2 (0.7)	1 (0.3)
Unknown/not reported	6 (2.0)	7 (2.2)
Ethnicity, n (%)		
Not Hispanic/Latino	224 (73.2)	245 (79.3)
Hispanic/Latino	80 (26.1)	61 (19.7)
Not reported	2 (0.7)	3 (1.0)
Previous COVID-19, n (%)	302 (98.7)	5 (1.6)
PCR, n (%)		
Negative	306 (100)*	309 (100) ⁺
Positive	0	0
Anti-N/PCR status, n (%) [‡]		
Positive	306 (100)	215 (69.6)
Negative	0	94 (30.4)
Time between previous COVID-19 vaccine and		
study vaccination, days		
Mean (SD)	NA	438.2 (177.32)
Median (IQR)	NA	361 (314–623)

486 **Table 1.** Participant baseline demographics and characteristics in the per-protocol analysis set

487 *Five participants with missing PCR status at baseline were imputed as negative in part 2.

488 ^tTwo participants with missing PCR status at baseline were imputed as negative in part 1.

489 ^{*}Participants with a positive result for either anti-N or PCR are reported.

490

491

493 **Table 2.** Neutralizing antibody titers (GMT* ID₅₀) for Omicron XBB.1.5 (Primary endpoint; per-protocol

494 analysis set)

	Vaccine-naive	Vaccinated
	(N=306)	(N=309)
Day-0 GMT [†]	67.6	120.8
(95% CI)	(56.8–80.4)	(101.5–143.8)
Day-28 GMT	1303.7	955.5
(95% CI)	(1087.4–1563.0)	(814.0–1121.4)
Day-28–adjusted GMT	1491.5	841.4
(95% CI)	(1277.5–1741.4)	(723.9–978.0)
GMTR	1.8	
(95% CI)	(1.43–2.20)	
Day-28 SRR, %	74.3	64.3
(95% CI)	(68.9–79.3)	(58.6–69.6)
Difference in SRR, %	10.0	
(95% CI)	(2.6–17.4)	

495 *The 95% CIs for GMT and GMTR are calculated based on the t-distribution of the log-transformed

496 values, then back transformed to the original scale.

⁴97 [†]Day-0 GMT is the last non-missing result before study vaccination.

498

500 **Table 3.** Summary of solicited and unsolicited TEAEs in vaccine-naive and previously vaccinated

501 participants (Safety analysis set)

	Vaccine-naive (N=338)	Vaccinated (N=332)
Solicited AEs, n (%)	202 (59.8)	227 (68.4)
Grade ≥3	9 (2.7)	5 (1.5)
Local	140 (41.4)	189 (56.9)
Grade ≥3	3 (0.9)	1 (0.3)
Systemic	164 (48.5)	158 (47.6)
Grade ≥3	7 (2.1)	4 (1.2)
Unsolicited TEAEs, n (%)		
Any	18 (5.3)	29 (8.7)
Treatment-related	1 (0.3)	5 (1.5)
Severe TEAEs, n (%)	1 (0.3)*	2 (0.6) ⁺
Treatment-related	0	0
Serious TEAE, n (%)	1 (0.3)*	2 (0.6) ⁺
Treatment-related	0	0
Medically attended AE, n (%)	8 (2.4)	14 (4.2)
Severe	0	2 (0.6) ⁺
Treatment-related	0	1 (0.3) ⁺
AESI, n (%) [‡]	0	0
TEAEs leading to study discontinuation, n (%)	0	0
Death, n (%)	0	0

502

503 *The severe/serious TEAE was obstructive pancreatitis.

^{*}Severe/serious TEAEs and medically-attended, severe AEs were an appendiceal abscess and a

505 gastrointestinal stromal tumor. The related medically attended AE was hypertension.

^{*}AESIs include potential immune-mediated medical conditions and AEs specific to COVID-19 (i.e.,

507 myocarditis/pericarditis).

508

Figure legends

Figure 1. CONSORT diagram

Participants in the previously vaccinated (comparator) group were enrolled in part 1 of the 2019nCoV-313 study. Participants may have been excluded for more than one reason.

Figure 2. Neutralizing antibody responses to XBB.1.5 at days 0 and 28 post study vaccination (perprotocol analysis set)

(A) GMTs of nAb responses to XBB.1.5 in vaccine-naive and previously vaccinated participants. GMT values are shown on a log scale *y*-axis, and corresponding adjusted GMT values are shown above each respective bar. GMTRs (95% CI) are included comparing bracketed bars (noninferiority criterion: lower bound of the two-sided 95% CI for the GMTR > 0.67). (B) Cumulative distribution of nAb ID_{50} GMTs. (C) Top panel: GMTR (log-scale GMT ratio of vaccine-naive to previously vaccinated) with a lower bound of the two-sided 95% CI greater than 0.67 indicating noninferiority of vaccine-naive vs previously vaccinated. Bottom panel: a SRR difference (vaccine-naive – previously vaccinated) with a lower bound of the two-sided 95% CI greater than -10% indicating vaccine-naive non-inferiority to previously vaccinates the noninferiority region for vaccine-naive.

Figure 3. Pseudovirus neutralizing antibody responses to XBB.1.5 and emerging variants at days 0 and 28 post study vaccination in a subset of the vaccine-naive group (Per-protocol analysis subset)

Neutralizing antibody responses are shown in a subset of participants from the per-protocol analysis set (n=42). GMT values are shown on a log scale *y*-axis, and corresponding adjusted GMT values are shown above each respective bar. *Validated assays. [†]Fit for purpose assays.

Figure 4. Solicited local and systemic reactogenicity events in all participants (Safety analysis set)

Solicited (A) local and (B) systemic TEAEs within 7 days of study vaccination in participants who received study vaccination and completed at least one eDiary entry. The proportion of participants with a grade \geq 3 event is shown in gray text within the blue bars.



Figure 1. CONSORT diagram



Figure 2. nAb responses to XBB.1.5 at days 0 and 28 post study vaccination (per-protocol analysis set)



Figure 3. Pseudovirus nAb responses to XBB.1.5 and emerging variants at days 0 and 28 post study vaccination in a subset of the vaccine-naive group (per-protocol analysis subset)



Figure 4. Solicited local and systemic reactogenicity events in all participants (safety analysis set)

Vaccine-naive

Vaccinated



PCR=polymerase chain reaction.

Participants in the previously vaccinated (comparator) group were enrolled in part 1 of the 2019nCoV-313 study. Participants may have been excluded for more than one reason.







